Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203164
Status:
COMPLETED
Last Update Posted:
2010-03-09
First Post:
2005-09-13
Brief Title:
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinsons Disease Patients
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Bi-national Multicenter Double-Blind Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinsons Disease PD Patients With Motor Fluctuations Treated With Chronic LevodopaCarbidopa Therapy
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to look at the effectiveness tolerability and safety of one dose of rasagiline in advanced Parkinsons disease PD patients who have been treated with LevodopaCarbidopa therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None